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Premonitory pain preceding swelling: a distinctive clinical presentation
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Abstract
Purpose: The aim of this paper is to document the unusual presentation of long-standing pain at the tumour site before
development of a swelling in patients with synovial sarcoma.
Patients/methods and results: The clinical presentation of 53 patients with synovial sarcoma was compared with 56 randomly
selected patients with other sarcomas of the trunk and extremities. The two groups were similar with regard to age
(P¼0.980), sex (P¼0.784) duration of symptoms (P¼0.697), size (P¼0.931) and site of tumour (P¼0.288). Sixteen
(30.2%) patients with synovial sarcoma had pain before development of a swelling compared to two (3.6%) patients with
other sarcomas (P<0.001, odds ratio¼11.68, 95% confidence interval 2.53, 53.83). The mean duration of such pain was
37 months (median 24, range 6–120 months). The nature of the pain was variable. Eight patients had sharply localised
tenderness. Calcification seen in the X-rays of four patients was initially misdiagnosed as benign lesions. A swelling was
ultimately detected by MRI, CT, ultrasound or at physical examination. The mean duration from first presentation with pain
till diagnosis of synovial sarcoma was 20 months. In three patients, at explorative surgery there was friable, vascular or
necrotic tissue in the absence of a well-defined tumour mass.
Discussion: The occurrence of long-standing pain at the tumour site prior to development of a swelling is significantly more
common with synovial sarcomas than with other sarcomas. Awareness of this unusual presentation and appropriate
investigation may enable detection of synovial sarcoma at a prognostically favourable early stage.
Key words: synovial sarcoma, pain, diagnosis, clinical features
Introduction
Synovial sarcoma is a clinically and morphologically
distinct neoplasm of uncertain histogenesis mostly
affecting the extremities of adolescents and young
adults. It is the fourth commonest soft tissue sarcoma
in adults,
1 with approximately 150 new cases a year
in the UK and 650 in the USA.
2 It is regarded as an
aggressive neoplasm with reported 5- and 10-year
survival rates ranging, respectively, from 38 to 76%
3,4
to 20 to 63%.
5,4 The usual presenting symptom
is of a swelling with or without pain.
1,3,6 The
duration of symptoms ranges from 1 month to 20
years,
3 with a mean of 2.5 years.
7 We have observed
that some patients with synovial sarcoma have long
standing pain at the tumour site for variable periods
of time prior to development of a swelling. This
phenomenon has been briefly mentioned, mostly
in older literature,
7,8 and in more recent isolated case
reports.
9,10 In order to determine if this presentation
was unique to synovial sarcoma, we compared the
clinical features of 53 patients with synovial sarcoma
with those of 56 patients with other types of sarcomas
involving the trunk and extremities. In this report we
describe the variable clinical presentations, patholo-
gical features and survival outcome of 16 patients
with synovial sarcoma who had pain at the tumour
site prior to development of a swelling. As numerous
studies
3,5,6,11,12 have reported that a tumour size
smaller than 5cm is associated with a better prognosis
insynovial sarcoma,awareness ofthis unusualclinical
presentation and attempts to identify synovial sarco-
mas at an early stage may be of benefit to patients.
Patients and methods
The clinical presentation of 53 patients with synovial
sarcoma in the Scottish Bone Tumour Registry from
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patients with other sarcomas involving the trunk and
extremities using the chi-square test. A P value of less
than 0.05 was considered to be statistically signifi-
cant. The other sarcomas were randomly selected
from sarcomas of the extremities and trunk affecting
a similar age group. These comprised 13 epithelioid
sarcomas, 10 clear cell sarcomas, nine myxoid
liposarcomas, seven alveolar rhabdomyosarcomas,
seven extraskeletal myxoid chondrosarcomas, four
leiomyosarcomas, three low-grade fibromyxoid
sarcomas and three malignant fibrous histiocytomas.
The clinical features were obtained from the records
of the tumour registry, which had detailed accounts
of the clinical features. The diagnosis was confirmed
by review of the histology slides. The mean survival
time of patients with synovial sarcoma and the effect
of initial pain on recurrence, metastases and tumour-
related death was estimated by the Kaplan–Meier
method and log rank test. All statistical analysis was
done using SPSS version 10.0.
Results
Sixteen out of 53 (30.2%) patients with synovial
sarcoma had pain at the site of the tumour before
development of a swelling, compared to two out of
56 (3.6%) patients with other types of sarcomas.
This difference was statistically significant (P<0.001,
odds ratio¼11.68, 95% confidence interval 2.52,
53.83). There was no statistically significant differ-
ence in the patients with synovial sarcomas and other
sarcomas with regard to age (P¼0.980, t-test, mean
difference 0.09 years, 95% CI  7.4, 7.6), duration
of symptoms (P¼0.697, t-test, mean difference
 3.70 months, 95% CI –22.51, 15.1), size of
tumour (P¼0.931, t-test, mean difference 0.93cm,
95% CI –0.97, 2.83), sex (Pearson 
2
¼0.075, df¼1,
P¼0.784) and site of tumour (Pearson 
2
¼18.634,
df¼16, P¼0.288).
The clinical details of the 16 patients with synovial
sarcoma who had pain at the site of tumour prior to a
swelling are summarised in Table 1. There were 11
females and five males. The mean age of patients was
33.4 years (range 10–77 years). The mean duration
of pain prior to swelling was 36.6 months (median
24, range 6–120 months).
Fourteen patients presented initially to a doctor
because of pain. Two patients (cases 11 and 15)
presented with a swelling but gave a history of pain
at the site, prior to development of the swelling.
The nature of the pain was variable. In some it was
sharply localised, in others it radiated down a limb.
It was described as sharp, shooting or cramp like.
Movement and knocking or jarring the site usually
aggravated pain. Two patients (cases 2 & 15) who
later developed tumours in the thigh complained
that sitting had been uncomfortable. Two patients
(cases 3 & 12) with subsequent tumours in the feet,
complained that bearing weight on the ankle first
thing in the morning or after sitting for long periods
was painful. One patient (case 7) who had a tumour
in the abdominal wall presented twice to accident
and emergency for pain in the right iliac fossa. She
had complained of pain off and on at the site for
2 years. Eight patients had sharply localised tender-
ness. Case 14 was unusual as she had bilateral
enucleation of eyes for retinoblastoma at 5 months
and 3 years of age.
Two patients had received steroid injections with-
out being investigated radiologically. X-rays were
done in eight patients for investigation of pain. They
were normal in four and showed calcification in the
others. These were diagnosed as phleboliths in a
haemangioma (this patient also had abnormal signals
on MRI interpreted as a haemangioma), calcific
tendonitis or loose bodies. In two patients X-ray and
computed tomography (CT) done after appearance
of the swelling showed calcification. In one patient
(case 4) ultrasound, bone scan and repeated mag-
netic resonance imaging (MRI) had been normal
(these were not available for review). In another
patient (case 13) two surgical explorations failed to
reveal any abnormalities. The swelling was ultimately
picked up by MRI in two patients (mean tumour
size 5.5cm), ultrasound in two (mean size 4.2cm),
CT scan and ultrasound in two (mean size 7cm) and
surgical exploration in two (mean size 2.8cm). In six
a palpable mass was ultimately detected at physical
examination (mean size 4cm), while two patients
noticed the swelling themselves (mean size 8.5cm).
The mean duration from first presentation to a
doctor with the pain, until diagnosis of synovial
sarcoma was 20 months (range 1 week to 144
months).
Twelve patients were treated by surgical excision
and four by amputation. In case 1, at surgery there
was an ill-defined area of calcification surrounding
and invading a nerve. In case 3, there was no definite
tumour mass at surgery but blood stained soft tissue
was seen extending around the tibial artery.
Similarly, in case 7, there was only soft necrotic
material with no obvious tumour mass. One patient
had preoperative and three had postoperative che-
motherapy. One patient had preoperative and two
had postoperative radiotherapy. Six patients had
local recurrence, nine had metastases and 10 died
of the disease. The mean survival period was 91
months (95% CI 55, 127). Live patients were
followed up for a mean period of 73 months (range
48–144 months). One patient was alive with meta-
stases after 54 months of follow-up. The presence of
pain before onset of swelling showed no significant
association with recurrence (log rank P¼0.631),
metastases (log rank P¼0.533) and tumour related
death (log rank P¼0.472).
Of the only two patients with other sarcomas who
experienced pain at the site of the tumour prior to a
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No
Age
and sex Site
Duration of
pain (months)
prior to swelling
Initial investigations
for pain*
Detection of
swelling Initial diagnosis
Time from
presentation
to definitive
diagnosisy
Outcome and
follow-up
(months)z
1 11, M Thigh 24 X-ray-calcification,
MRI-abnormal signal
Clinical examination Haemangioma 17 months AWND, 48
2 77, F Thigh 36 X-ray-calcification MRI NK 34 months AWND, 84
3 23, F Foot 60 X-ray-normal MRI NK 24 months AWND, 60
4 39, M Foot 65 X-ray, bone scan,
Ultrasound, MRI-normal
Clinical examination NK 65 months Died, 20
5 53, F Elbow 7 X-ray-calcification Ultrasound Calcific tendonitis 9 months AWND, 49
6 26, F Buttock 15 Initially-none,
had steroid injection
CT scan, ultrasound Trochanteric bursitis 8 months Died, 40
7 10, F Abdominal wall 24 None CT scan, ultrasound NK 1 week Died, 41
8 65, M Knee 6 X-ray-calcification Surgical exploration Loose bodies 6 months Died, 28
9 45, F Knee 120 X-ray-normal,
had steroid injection
Surgical exploration Chronic tendonitis 36 months AWND, 144
10 28, M Knee 6 None Ultrasound Ruptured popliteal cyst 2 months Died, 12
11 56, F Upper arm 60 None Noticed by patient NK 2 weeks Died, 37
12 14, F Foot 18 Had steroid injection Clinical examination NK 18 months Died, 36
13 15, M Knee 84 X-ray-normal,
surgical exploration
(done twice)-normal
Clinical examination NK 72 months Died, 170
14 12, F Thigh Several years None Clinical examination NK Not known Died, 44
15 28, F Thigh 18 None Noticed by patient NK 1 week Died, 15
16 33, F Knee 48 None Clinical examination Meniscal injury 14 months AM, 54
*Indicates investigations done until detection of the swelling.
yIndicates time from first presentation to a doctor until histological diagnosis.
zIndicates period of follow-up from definitive diagnosis.
AWND, alive and well with no disease; AM, alive with metastases; NK, not known.
All the patients who died did so due to the synovial sarcoma.
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3swelling, one was a 10-year-old boy who had an
epithelioid sarcoma of the hand and the other was a
78-year-old man who had an extraskeletal myxoid
chondrosarcoma of the axilla.
Discussion
This study shows that patients with synovial sar-
comas are 12 times more likely (P<0.001, odds
ratio¼11.68, 95% confidence interval 2.52, 53.83)
to have pain at the site of the tumour prior to
development of a swelling, than patients with other
sarcomas affecting the extremities and trunk. The
occurrence of sharply localised pain usually asso-
ciated with tenderness, necessitating a visit to a
doctor in 30.2% of the patients with synovial
sarcoma in our tumour registry, made us give
credence to this unusual presentation.
Slightly more than half the patients with synovial
sarcoma who present with a swelling may have
associated pain and tenderness.
1,7 In the series
reported by Wright et al., 137 out of 180 patients
had pain arising directly from the lesion while 27 had
referred pain due to pressure.
3 Such pain, which is
also seen with other sarcomas, is probably due to
expansion, stretching and destruction of surrounding
tissues and haemorrhage and necrosis within the
tumour. The presence of pain preceding the swelling
in synovial sarcoma has not been described in most
previous large studies. In the series of 134 synovial
sarcomas reported by Cadman et al.,
7 26.9% had
pain or point tenderness for periods ranging from
1 month to 18 years (mean 3.5 years) prior to
appearance of a palpable mass. Haagensen and
Stout,
8 mentioned this unusual presentation in
their series and commented that the knee was
explored in a number of patients, although details
are not provided. Ours is the first large series to
describe the clinical presentation, histological fea-
tures and outcome of patients with synovial sarcoma
who had pain prior to development of a swelling.
Awareness of this presentation and prompt inves-
tigation may enable detection of synovial sarcoma at
an early stage. This may be of benefit to patients as
numerous studies have reported a better prognosis
with synovial sarcomas measuring less than 5cm in
diameter.
3,5,6,11,12 In our series, the patients who
presented with pain preceding the swelling did not
have a better survival than those without preceding
pain. This is probably because diagnosis was delayed
in most patients with a mean time of 20 months from
first presentation to a doctor. Calcification in X-rays
though detected early was misdiagnosed as calcific
tendonitis or loose bodies. Synovial sarcoma should
always be considered in the differential diagnosis
of a soft tissue mass with amorphous calcification.
13
Calcification in synovial sarcoma may manifest as
fine stippling, small spotty radiopacities or as more
dense areas.
1,14 In our series, other than in one
patient, ultrasound, CT scan or MRI whenever they
were performed helped to detect a swelling. CT and
MRI do not provide a specific or diagnostic picture
but will show a para-articular heterogeneous septate
mass.
1,15 Previous studies
8 have mentioned surgical
exploration failing to detect swellings, as was seen in
one of our patients. It is noteworthy that in our
series, in three patients there was no obvious tumour
mass at surgical exploration. The tissues biopsied
were described as ‘necrotic material’ or ‘haemor-
rhagic soft tissue’. Synovial sarcomas can manifest as
poorly circumscribed variegated areas with a friable
or shaggy appearance with haemorrhage, necrosis or
cyst formation.
1 Thus it is important to biopsy such
abnormal looking tissue, especially in the context of
long-standing unexplained pain. Ichinose et al. have
described a patient who presented with a severe spot
of tenderness on the thigh.
9 A biopsy of the area
showed a microscopic synovial sarcoma in the fascia
just deep to the subcutis.
The mechanism for this premonitory pain is
difficult to explain. As it occurs at a time when the
tumours are small, pressure effects on the surround-
ing tissues or haemorrhage or necrosis within the
tumour are unlikely to be major causes of pain as in
the case of other sarcomas presenting as swellings
associated with pain. As the synovial sarcomas and
the other sarcomas in our study were similar in
respect to age and sex of patient, duration of
symptoms and site and size of tumour, the pain
seems to be intrinsically related to the biological
behaviour of synovial sarcoma. It may be due to
release of cytokines, prostaglandins and other
inflammatory mediators by the tumour and requires
further investigation. Synovial sarcoma cells stimu-
lated by interleukin-1b have been shown to produce
various cytokines including tumour necrosis factor a
in vitro
16 and there is a report of an interleukin-1a
producing synovial sarcoma in a patient who had
prolonged fever.
17 Conversely, one study has shown
that prostaglandin (PGE2) production by synovial
sarcoma was low.
18
The possibility of detecting soft tissue sarcomas at
a pretumour stage is a challenging prospect. The use
of CT-guided core needle biopsy may be particularly
useful if an abnormal area is detected by CT or MRI.
As pain related to joints is a common symptom, it
will not be feasible to investigate all such patients by
CT or MRI. Prudent, appropriately timed, use of
radiological investigations in patients with persistent
unexplained sharply localised pain may help to detect
synovial sarcomas at a stage when they are associated
with a better prognosis.
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